Independent Re-Adjudication Of RECORD Confirms Safety Of Rosiglitazone

An independent re-adjudication of the RECORD trial has confirmed the original findings of the trial, that rosiglitazone d0es not increase cardiovascular risk. But critics of the trial and the drug are unlikely to be appeased by the new result.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news